Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatmen...